Raymond James & Associates Passage Bio, Inc. Transaction History

Raymond James & Associates

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 11, 2021	SELL	$12.44 - $19.45 $657,901 - $1.03 Million	-52,886 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$16.24 - $29.83 $409,686 - $752,521	25,227 Added 91.21%	52,886 $924,000
Q4 2020 Feb 12, 2021	BUY	$14.28 - $29.73 $130,790 - $272,297	9,159 Added 49.51%	27,659 $707,000
Q3 2020 Nov 04, 2020	BUY	$12.39 - $26.15 $229,215 - $483,775	18,500 New	18,500 $243,000

32.7M

8.3K

400

Ticker PASG
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,463,200
Market Cap $38.1M
Description
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 ...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.